Trial · NCT02943239
Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
NCT02943239, Phase 1, Completed, Regeneron Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men. Trials, record NCT02943239. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02943239
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
- NCT number
- NCT02943239
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 82 participants, actual
- Lead sponsor
- Regeneron Pharmaceuticals
- Conditions
- Healthy Volunteers
- Interventions
- REGN1033, REGN2477, Placebo
- First posted
- 2016-10-24
- Last updated
- 2024-08-09
- Other registries' IDs
- eudract:2016-002979-95
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of treatment-emergent adverse events (TEAEs) | Up to 40 weeks | |
| Secondary | Percent change in thigh muscle volume as measured by MRI | Up to 28 weeks | |
| Secondary | Change in thigh muscle volume as measured by MRI | Up to 28 weeks | |
| Secondary | Percent change in total and regional body composition as measured by Dual X-ray absorptiometry (DXA) | Up to 28 weeks | |
| Secondary | Change in total body composition as measured by DXA | Up to 28 weeks | |
| Secondary | Change in regional body composition as measured by DXA | Up to 28 weeks | |
| Secondary | Pharmacokinetic profile of REGN2477 assessed via measurement of concentrations of REGN2477 in serum over time | Up to 40 weeks | |
| Secondary | Pharmacokinetic profile of REGN1033 assessed via measurement of concentrations of REGN1033 in serum overtime | Up to 40 weeks | |
| Secondary | Change in total Activin A levels in blood | Up to 40 weeks | |
| Secondary | Change in total GDF8 levels in blood | Up to 32 weeks |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40360471 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02943239
GET https://conductscience.org/api/trials/v1/NCT02943239/registered